drugset
drugset / Trial / NCT01159301

Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia

NCT01159301 ↗

Phase 1 Terminated 44 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and the best dose of entinostat when given together with sorafenib tosylate in treating patients with advanced or metastatic solid tumors or refractory or relapsed acute myeloid leukemia. Entinostat and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2010-06
Primary completion
2013-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule — Oral
Subject Sorafenib Small molecule — Oral

Indications

acute basophilic leukemia acute megakaryoblastic leukemia acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myelomonocytic leukemia M4 adult acute monocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive cancer of unknown primary site erythroleukemia